SYNCHRONIZE™-1: Survodutide Phase 3 trial (NCT06066515)
A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 726
- actual
- Start
- 25 Nov 2023 (actual)
- Primary completion
- 2 Dec 2025 (actual)
- Sponsor
- Boehringer Ingelheim
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Survodutide 3.6 mg | Experimental | Combination Product: survodutide | Not stated |
| Survodutide 6.0 mg | Experimental | Combination Product: survodutide | Not stated |
| Placebo | Placebo comparator | Combination Product: Placebo | Not stated |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage change in body weight from baseline to Week 76 | Baseline and at Week 76 |
| Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
| Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
| Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in body weight (kg) | Baseline and Week 76 |
| Absolute change from baseline to Week 76 in waist circumference (cm) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of the Eating Behaviour patient reported outcome (PRO) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in Eating Behaviour PRO total score | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in HbA1c (mmol/mol) | Baseline and at Week 76 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
SYNCHRONIZE-1 in adults with obesity
Adults with a BMI of 30 or higher, or 27 or higher with a complication, were randomised 1:1:1 to survodutide up to 3.6 mg, up to 6.0 mg, or placebo.[2]
At week 76 weight changed by -12.2% (3.6 mg), -13.0% (6.0 mg) and -5.4% (placebo), with at least 5% loss in 72.6%, 71.9% and 46.3%.[2]
Gastrointestinal events occurred in 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group and 47.9% of the placebo group.[2]
No deaths were reported.[2]
Sources
- 1A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026
Found an error? Report a correction.